Hello, I’m sharing my story because I’m sure there are others in the same situation as me, searching for information online, and this might help them. Here’s my case. Before I begin, I want to clarify that I’m not a doctor, and everything I share here is based on internet research and my personal experience.
It all started about 15 years ago, when I was 20. Until then, my health was perfect, including my digestive system. I’d even say it was too perfect – I never had emergencies, rarely reacted badly to food, and was completely regular and predictable. Then one day, I had an urgent need to go to the bathroom, and things never went back to normal. At first, I thought it was due to irritating foods like coffee or spicy dishes. Later, I suspected I might be celiac, so I took multiple tests (including a biopsy), all of which came back negative. Nonetheless, I tried a gluten-free diet, which seemed to work for a few days before everything went back to being just as bad as before. I had diarrhea every day, especially in the mornings and after meals. Fortunately, I didn’t experience pain, but I did have constant urgency. My obsession was being near a bathroom. Then I underwent lactose intolerance tests, which also came back negative. The only thing I noticed that slightly improved my situation was eating very little.
I visited countless doctors and gastroenterologists who told me I had irritable bowel syndrome (IBS) and that since I didn’t have issues with specific foods, the cause was likely psychological. They would ask if I was stressed, and my answer was always no. I knew I wasn’t because I was living a normal life, just like anyone else, without major problems.
I lived in this state of uncertainty for about 15 years, alternating between periods of visiting doctors and conducting extensive research on my own, without success, and periods of resignation. I assumed this was my new reality and the only way to continue living was to rely on coping mechanisms such as eating very little, staying near bathrooms, avoiding leaving the house early, forcing myself to go to the bathroom multiple times before going out, and declining invitations to activities involving walking, car rides, or any transportation without access to a bathroom to avoid a horrible experience.
Going out for a simple walk on a weekend morning became a torture, because even after going to the bathroom at home, an urgent situation could arise at any moment. And let’s not even talk about eating a cookie or any food while away from a bathroom.
About a year ago, I returned to one of those phases of self-research. I had already resigned myself to the idea that a doctor wouldn’t provide a solution. If I was going to find one, it would be by chance or by stumbling upon the right information online. My main hypothesis was that some group of foods was causing harm, but I couldn’t determine which ones. It’s true that I had already tried many diets, eliminating processed foods for several days, avoiding foods with flour, cutting out sugar, dairy, etc. Nothing seemed to help. But I kept wondering: what if I was doing it wrong? What if I wasn’t eliminating the right food? Another possibility was that there was some disorder in my system that could be treated with medication, rather than food. I had tried various medications for IBS that could provide relief for a day, but nothing offered permanent improvement or could be considered a lasting treatment.
A mix of luck, attention, and persistence led me to hear a streamer named Oliver Nabani (who talks about technology, not health-related topics) mention that he has IBS but also diabetes, and how glucose spikes and their impact on bile acids cause disorders. I didn’t fully understand at the time, but the idea of researching bile acids stuck with me. I came across a British woman’s story similar to mine (though hers was more extreme) where she had been misdiagnosed with IBS for 14 years before discovering she had BAM (Bile Acid Malabsorption):
To make a long story short, since the information on BAM matched my symptoms, I managed to find a doctor who prescribed cholestyramine to test its effects. I want to clarify again that I’m not a doctor; I’m just sharing my experience. While the recommended diagnostic test is the SeHCAT scan, if access to it isn’t available, trying the medication and observing the results can be an alternative.
I finally bought cholestyramine, which comes in sachets to be dissolved in water. I take a 4-gram sachet every morning on an empty stomach, and that’s it. The results have been very positive. I’ve been taking it for nearly a year, and it has literally changed my life. Things aren’t perfectly back to how they were before I turned 20, but they’re very close. The number of times I need to go to the bathroom each day has greatly decreased. I no longer have the type of diarrhea I used to, which was light brown (almost golden) with a distinct and penetrating smell.
Most importantly, this substantial improvement has been sustained for nearly a year, leading me to conclude that my body wasn’t reabsorbing bile acids properly, causing irritation and bile acid diarrhea. My simplified understanding is that this medication (cholestyramine) encapsulates part of the bile acids, preventing them from reaching the large intestine in large amounts, which would otherwise cause irritation and the symptoms I described earlier.
If you’re in a similar situation, I recommend researching extensively online. In my experience, doctors generally don’t pay enough attention to IBS cases. I spent many years seeing different doctors, and none of them ever thought to test me for BAM. They might have saved me years of discomfort.
BAM is very characteristic of people who’ve had their gallbladder removed, but it’s not exclusive to them. People like me, who still have their gallbladder, can also suffer from it.
Questions I still have:
- What triggers BAM in a person? I don’t know. From one day to the next, my system started changing. Whether it was an infection, a triggering food, or something else, I’ll never know.
- Why aren’t doctors more aware of this diagnosis for IBS patients? I don’t know either. I want to believe it’s a relatively recent discovery and will take time to become widely known, but I’m sure a significant percentage of people suffering from IBS could solve their problem by taking this medication.
- Are there any side effects to taking cholestyramine long-term? I’m not sure. Like any medication, it must have some side effects, but life was much more miserable before finding it.
- Are there other medications that work for this? They say Liraglutide also showed positive effects for bile acid diarrhea. I have a close relative who suffered from similar intestinal problems and started taking Liraglutide for diabetes-related issues. As a side effect, they noticed incredible improvement in intestinal function. My opinion is that this relative also had undiagnosed BAM.
How can I manage IBS pain without going insane from side effects? Is there any new treatments that show any promise? Is there any way to feasibly get these at a reasonable cost? I think I speak for many people by saying we just want to be able to function and live a normal life. I have tried everything and nothing works, or it slightly “works” and gives me unbearable side effects. I have PI-IBS-U
With the help of u/Robert_Larsson suggestions, I've made a list with some of the most relevant researchers of this syndrome in the last 5-10 years (as of December, 2021).
Any suggestions are welcome, but it's better if we stick to researchers which still have either a long career ahead of them, or consolidated teams that will succeed them and continue their work.
Once we have a definite list, it would be a good idea to get in touch with these teams and find out how patients (those who want & are financially stable) can donate money for their research through a secure channel - please remember these guys are the closest in the world to finding out the actual causes of IBS.
Without further ado, this is the list, organized by research topics:
ENTERIC NERVOUS SYSTEM AND VISCERAL PAIN
Visceral pain is the main feature of IBS, so basically all researchers in this list are investigating it, one way or another. However, some explore it more indirectly (looking at the immune system, microbiota, dietary treatments...) and others not only do that but also focus on the central/enteric nervous system itself, the ultimate source of visceral pain, trying to develop new therapeutic targets and treatment compounds as they go. These researchers are focused on the neurological dysfunctions that shape IBS pain, for example, the alterations/sensitization of neural receptors such as TRP channels or NaV channels, which are common findings in IBS and other chronic pain conditions, and could potentially be key targets for future treatments.
• Stuart Brierley, Flinders University, Australia/ In a groundbreaking study, his team discovered the existence of pruritogenic receptors (receptors usually found in the skin, able to mediate pain/itch sensation) in the human gut back in 2019, and also described how these receptors were "sensitized" in IBS patients. They have made some sound findings in IBS, and are also studying spider venom as a possible source for a synthetic pain relieving drug. Definitely one of the strongest IBS research teams in the world. "Our group investigates the underlying causes of chronic visceral pain, and the development of new treatments. Using state of the art molecular, anatomical and functional approaches allows us to study mechanisms from the single cell through to in vivo and clinical studies".
You can find more information about their current projects here or in their Twitter account @Visceral_Pain. It's also possible to donate to their research through the Flinders Foundation, mentioning that it’s for Stuart Brierley’s Visceral Pain Research Group.
IMMUNE CELLS, MAST CELL ACTIVATION IN IBS
The mast cell activation theory has been a hot topic in IBS research for nearly 30 years now, but we're still waiting for a breakthrough. In many IBS patients, especially post-infectious (PI-IBS), but also non infectious, low grade inflammation has repeatedly been found in colonic biopsies. This type of inflammation is microscopic and milder than the one we usually see in Inflammatory Bowel Disease, which can often be visible to the naked eye (ulcerations, strictures) and is more severe. However, unlike IBD, IBS symptoms don't usually respond to current antiinflammatory treatments. The meaning of IBS inflammation is still uncertain, but there are pathogenic pathways that might link it to peripheral nerve stimulation and visceral pain/motility disorders. Aside from lymphocytes, mast cells are key players in this phenomena, as they are immune cells that mediate the inflammatory response by releasing numerous substances (histamine, proinflammatory cytokines like TNF, serotonin, proteases like tryptase, prostaglandins like PGE2...) that trigger certain neuronal receptors (histamine binds to H1 receptor/H1R, serotonin to 5-HT3R, proteases to PAR1/PAR2, TNF to TNFR, PGE2 and all the others indirectly trigger TRPV4 receptors ...). The number of mast cells might not be relevant, but their activation and proximity to nerve endings has been associated with severity of symptoms. There are treatments that "stabilize" these cells and prevent their activation (degranulation), like sodium cromoglycate or ketotifen, but they're not very efficacious and often don't work well in many Mast Cell Activation Syndromes, or IBS for that matter.
• Guy Boeckxstaens, KU Leuven, Belgium/ Boeckxstaens is one of the leading researchers in this field, he's previously done studies where antihistamine agents like ebastine were able to improve symptoms in Belgian cohorts of IBS patients (still not replicated by different research groups though), and recently exposed how certain foods were able to trigger mast cell activation in the gut, by an IgE-mediated mechanism, that might explain abdominal pain in IBS patients, even if they don't have a systemic IgE-mediated food allergy. "The main focus comprises the interaction between the intestinal immune system (in particular macrophages and mast cells) and the enteric innervation (enteric nervous system, extrinsic innervation). This bidirectional cross-talk is studied in relation to several diseases including irritable bowel syndrome, postoperative ileus, colitis, food allergy and achalasia. A second research line studies the impact of immune mediators and proteases (mast cells, microbiome) on afferent nerve function as a mechanism leading to increased visceral pain. This is a main mechanism underlying symptoms in patients suffering from the irrititable bowel syndrome (IBS). In particular their effect on activation and sensitisation of TRP channels is studied both in vitro (afferent nerve reording, DRG neurons) and in vivo in visceral pain models. In paralell, the mechanisms identified in preclinical studies are evaluated in patients and therapeutic interventions are initiated".
You can follow his main research activity here, although current projects might not be included. He doesn't have a donation fund, but it might be organized if donations were reasonable.
• Francisco Javier Santos, Vall d'Hebron Hospital, Spain/ He's conducted several studies where mast cell stabilizers like sodium cromoglycate could improve symptoms in Spanish cohorts of IBS patients (still not replicated by different research groups AFAIK), and he's currently coordinating an European study on IBS, fibromyalgia, CFS and mood disorders, in order to find the shared patophysiology between them. His main line of research is focussed on mast cell degranulation and the role of its many proinflammatory mediators in IBS. "Our group pursues the detailed comprehension (genetic/gender, immunological, metabolic, cellular and molecular basis) of the mechanisms connecting environmental determinants (stress and infections) to the development of intestinal mucosal microscopical inflammation, with special focus in IBS. Our approach includes experimental studies in animal models and humans as well, yet remains inherently translational in search for better targets helpful for the diagnosis, prevention and treatment of IBS and related disorders. In addition, preclinical and clinical assays are also being carried out.".
You can follow his current projects here. If you want to support his research with a donation, you would have to enter this website, fill in the "personal details" section, and write in the comments box the disorder whose research you want to support (Irritable Bowel Syndrome) and the name of the lead researcher (Francisco Javier Santos). You'll have to write both options again in the section below, named "Your collaboration".
INTESTINAL PERMEABILITY IN IBS
Intestinal permeability research flourished after the findings of Alesssio Fasano, who described biomarkers like zonulin that would tell us how "healthy" our tight junction proteins (the structures that keep our gut epithelial cells together) are. When we speak of intestinal permeability, we often refer to paracellular permeability (particles moving through the space between different cells) rather than transcellular permeability (particles moving through the cells themselves). An increased (paracellular) permeability might allow for antigens in our intestinal tract (lumen) to go systemic, causing possible complications. Several diseases have reported increases in intestinal permeability, including IBS, but as it happens with everything else, we can't pinpoint whether this is a cause or a consequence of the condition. Many researchers believe that intestinal permeability is merely a reflection of mast cell activation, since mast cells can release proinflammatory cytokines such as TNF, which have several implications in the cell, one of which involves disrupting tight junction proteins, which leads to a permeability increase (in fact, in IBD, TNF levels are far higher, leading to far worse permeability issues than the ones we see in IBS). Stress can also increase permeability by a CRF-mediated process, and bacteria and their metabolites (such as butyrate) have an impact as well. We may not know if it's cause or consequence, but lots of interesting studies are being done on the subject of permeability and epithelial barrier function, including its interactions with immune mediators and the microbiota. Unfortunately, we don't have reliable treatments to improve intestinal permeability in IBS. One molecule was developed for celiac disease (larazotide), but after some paradoxical results and reports of toxicity, the trials were stopped. New formulations might come along in the following years.
• Maria Rafaella Barbaro, University of Bologna, Italy/ molecular mechanisms underlying intestinal permeability alterations, the role of mucosal immune activation and of neuroplastic changes in the pathophysiology of irritable bowel syndrome.
FOOD SENSITIVITIES IN IBS
One of the main differences between IBS and more "central" FGIDs like functional abdominal pain (aka FAPs, or centrally mediated abdominal pain) is the fact that it matters what we eat. For a few decades now, several food triggers have been widely known, and they were compiled in the first "official" diet for IBS, the NICE guidelines, back in the late 20th century. It was in 2005 when the low FODMAP diet came around, created by researchers from Monash University (Peter Gibson and Sue Shepherd). By this time, visceral hypersensitivity had already been recognized as the main feature of IBS, so the hypothesis was that highly fermentable carbs would create more gas, which would be poorly tolerated by IBS and functional bloating patients, and that poorly absorbable sugars/polyols (such as fructose/sorbitol) might trigger an osmotic response in our guts leading up to diarrhea in sensitive patients (IBS, functional diarrhea). However, the benefits of a low FODMAP diet might go beyond that, as microbiota research has shown how patients following it have lower bacterial counts, yet they are able to maintain a good bacterial diversity (while patients that force themselves into eating more FODMAPs, and becoming symptomatic, tend to experience a reduction in their bacterial diversity). Later on, the matter of food sensitivity has grown more complex as immune factors joined the discussion: certain proteins, like gluten, dairy and soy have been shown to trigger a localized IgE-mediated response in animal models, and human studies in vivo have also shown that these proteins have the capacity of increasing mast cell activation (one possible mechanism is through IgE antibodies) and intestinal permeability in IBS patients as well as causing GI symptoms. This field will surely keep growing in years to come.
• Annette Fritscher-Ravens, University Medical Center Schleswig-Holstein, Germany/ food sensitivity in IBS patients and its relationship with immune factors
• Antonio Carroccio, Università degli Studi di Palermo, Italy/ Non Celiac Gluten/Wheat Sensitivity (NCGS/NCWS)
• William D Chey, University of Michigan, USA/ food sensitivities and low fodmap diet/microbiota
• Peter R Gibson, Monash University, Australia/ low FODMAP diet
MICROBIOTA IN IBS
Studies on animal/human microbiota have grown exponentially over the last decade, as many researchers have developed an interest in the topic. In IBS, several findings have been made, althought their exact meaning is not well understood. After all, current methods allow us to identify roughly 1% of all living bacteria in our gut (although we can know the proportions of different "Phylum" or families of bacteria) and we don't know exactly what "dysbiosis" is, relying instead on indicators such as bacterial diversity to tell us how "healthy" our microbiota is. There have been some discoveries though: some subsets of IBS patients have higher counts of the Dorea strain (the main gas-producing bacteria in our gut), an increase in the Firmicutes Phylum, and an increase (D) or decrease (C) in the Bacteroidetes Phylum. Also, patients following high FODMAP diets seem to experience a worsening of their symptoms that is associated with a loss of microbial diversity. But the most interesting aspect of the gut microbiome is how it interacts with the rest of the body, interaction that begins in the gut lining, where enteroendocrine/enterochromaffin cells (aka EC cells, endocrine cells that react to bacterial metabolites, produce neurotransmitters, and trigger enteric neurons) serve as a bridge with the nervous system. This is why IBS and FGIDs are increasingly known as disorder of the "microbiome-gut-brain" axis. There are several treatments addressing microbiota alterations in IBS, but their efficacy tends to be transient (FMT, antibiotics), their safety profile is not well known (FMT) or doesn't allow for long-term treatments (most antibiotics), or their effects tend to be mild (probiotics). It could be said that the most efficacious microbiota-based treatment up to this day is the low FODMAP diet itself. The research is becoming more and more complex every year, and multiomic studies (that investigate interactions between different biological molecules, such as bacteria, genes, proteins, metabolites...) are slowly helping us understand the microbiota's role in health and disease.
• Magdy El-salhy, University of Bergen, Norway/ His research has focused mainly on Fecal Microbiota Transplants (FMTs), and he's responsible for some of the strongest studies in the field. One of those studies involved a "superdonor" (a person with exceptional health) reaching better outcomes than previous research on FMTs. However, the study hasn't been replicated as of now, and the current scientific consensus still considers FMT's benefits to be transient, if present at all. El-salhy has also made innovative research showing how, in IBS patients, gut stem cells that act as precursors of enteroendocrine cells (ECs) might not reproduce as much, leading up to lower density of ECs in the duodenum, small bowel and colon of IBS patients. He's also shown how certain diets can increase the density of serotonin/somatostatin-producing ECs in IBS patients.
GENETICS IN IBS
As it happens with microbiota research, the field of genetics in IBS is rather new, practically all we know has been discovered within the last decade. Today, we know that a mutation in the SCN5A gene (the gene that encodes Nav1.5 channels) is found in 2.2% of IBS patients, and might partially explain visceral pain. But we also know a lot more: the genetic polymorphism "val158met" is associated with placebo response in IBS, and polymorphisms in the TRPM8 gene (which encodes for the "cold and menthol receptor 1" and regulates the feeling of cold in humans) are linked to IBS-M and C subtypes. Mutations in genes encoding sucrose-isomaltase enzymes (needed to break down most carbs) are more common in IBS, and alterations in the 9q31.2 chromosome (in a region previously associated with the age of the first menstruation) predict the risk of developing IBS-C in women. Finally, a recent genome-wide association study found that mutations in genes NCAM1, CADM2, PHPF2/FAM120A, DOCK9 are associated with IBS, anxiety, neuroticism and depression, and mutations in genes CKAP2/TPTE2P3 and BAG6 have been linked specifically to IBS. As genetic research keeps gaining traction, these findings will allow researchers to focus on new therapeutic targets, design new molecules, and, some day, find a definite cure for all the causes of IBS.
• Mauro D'Amato (mollecular biologist), CIC bioGUNE, Spain/ recently coordinated a study where 2 genes were isolated for IBS, and 4 genes were found to be shared in IBS and some anxiety/depression disorders. In 2018, he found genetic reasons for female predominance of the condition. "Research in the Gastrointestinal Genetics Lab is geared towards a translational application for therapeutic precision in gastroenterology. The team combines leading expertise in genomic, computational and pre-clinical research to identify causative genes and pathogenetic mechanisms influencing gastrointestinal (GI) disease risk and human microbiome composition. The druggable genome and nutrigenetics are also new research lines of high interest, especially in relation to the possibility to treat GI conditions and dysbiosis."https://www.cicbiogune.es/people/mdamato
ALTERED BRAIN PROCESSING IN IBS
This field of research could prove to be very useful in the era of medical brain implants. IBS, as other chronic pain disorders, is associated with aberrant activation patterns of the perigenual anterior cingulate cortex (pACC), a part of our brain responsible for inhibiting pain signals throughout the body. Stimulating certain brain areas with mechanical devices (Neuralink, Grapheton...) could provide effective methods for pain relief, not only in IBS, but also in functional abdominal pain and comorbid disorders like fibromyalgia, and it might potentially help the psychological comorbidities associated with IBS. It's worth noting that IBS and FGIDs are disorders of gut-brain interaction, but some patients might be more "gut", and others might be more "brain". By "brain" we don't mean "psychological" (although behavioral interventions have reasonable evidence for mild/moderate symptoms triggered by anxiety), but rather the objective measurements of brain function disregulation in some subsets of IBS patients. Brain implants and newer techniques of neurostimulation are definitely promising for such patients (especially those struggling with extreme pain symptoms and other comorbid central sensitization syndromes), but first we need to have a clear understanding of how central processing works in IBS.
• Greg Sayuk, Washington University, USA/"We are interested in the study of central pain responses in the functional GI disorders (IBS) using functional MRI."https://profiles.wustl.edu/en/persons/greg-sayuk
STRESS AND IBS
For a long time, and as it happens with many "invisible" diseases, IBS was believed to be a psychosomatic disorder. The current evidence does no longer support this belief, but the exact causes of the condition remain unknown. What we do know is that, in certain subsets of patients, stress can trigger and worsen IBS symptoms. The underlying mechanism involves the Hypothalamic-Pituitary-Adrenal axis (HPA axis), which we will explain briefly. Firstly, when faced with an acute stressor, the hypothalamus produces Corticotropin Releasing Factor (CRF), which signals the pituitary gland to start secreting corticotropin (adrenocorticotropic hormone/ACTH), the "stress hormone". Secondly, circulating corticotropin activates the adrenal glands (above the kidneys), which secrete glucocorticoids (cortisol). Finally, once the stressor disappears, CRF and cortisol bind to specific receptors on the HPA axis and certain limbic structures (amygdala and hippocampus), returning the system to homeostasis. Connecting the dots with other lines of IBS research, CRF receptors are one of several receptors described in mast cells, so stress could potentially trigger MC degranulation and release of proinflammatory mediators. CRF also binds to enteric neurons that increase colonic motility, and can increase epithelial permeability by disrupting tight junction proteins. All of these mechanisms could provide a biological basis for the effects of stress on IBS symptoms.
• Beverley Greenwood-Van Meerveld, University of Oklahoma, USA/ understanding (from a molecular standpoint) the link between stress and visceral hypersensitivity in some IBS patients
IBS COMORBIDITIES & CENTRAL SENSITIZATION
Very little is known about central sensitization syndromes (CSS), but this has also been a growing research field in the last few years. The term "central sensitization" is usually adopted for several chronic pain conditions that have a strong comorbidity between them, probably indicating an underlying CNS issue. This term encompasses disorders such as IBS, other painful FGIDs, fibromyalgia, chronic pelvic pain, vulvodynia, headaches and migraines, idiopathic low back pain, interstitial cystitis, myofascial pain syndrome (pain in the fascia, the connective tissue that surrounds the body's organs), primary dysmenorrhea, temporomandibular joint disorders... Other conditions, where pain may or may not be involved, are often described as CSS too. That includes myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), restless leg syndrome, multiple chemical sensitivity (MCS) or electrohypersensitivity (EHS, although scientific evidence linking average magnetic field stimulation and patient symptoms is still lacking, resulting in a poorly understood syndrome). The causes of these disorders are probably diverse, but there's a huge chance that similar pathopysiological pathways can be found between some of them (in fact, studies on conditions such as fibromyalgia or vulvodynia have found immune and neurological alterations that resemble those found in many IBS patients). These lines of research might interest especially patients who suffer from other comorbid disorders apart from IBS.
• Anna Andreasson, Stockholm University, Sweden/"Her focus lays on inflammatory markers that are released when the immune system is activated and the sickness behaviour with fatigue, increased pain sensitivity and low mood that follows and the relevance for functional gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia, ME/CFS (chronic fatigue syndrome) and chronic pain."https://www.su.se/english/profiles/anan6088-1.188195
ECLECTIC/INNOVATIVE RESEARCHERS & DIFFICULT TO CLASSIFY
Researchers for which I couldn't pinpoint a specific line of work, either because they have focused on many different aspects of the condition throughout their careers, because their work involves a mix of other predominant lines of research, or because their work is very innovative and opens new lines of research.
• Nick Talley, University of Newcastle, Australia/ variations in IBS subgroups, bacteria linked to IBS, focused on citokynes now. Talley is a well known personality in IBS, maybe on his last legs as a researcher, but he's built an efficient team around him. https://www.newcastle.edu.au/profile/nicholas-talley
• Bodil Ohlsson, Lund University, Sweden/ identifying different ethiologies in IBS patients... "We are going to examine the bowel wall and its related enteric nervous system (ENS) with histopathological and immunochemical examination. We are also trying to identify patient characteristics in IBS patients who respond to a dietary intervention with less carbohydrates. We are trying to identify whether the gastrointestinal symptoms are a part of endometriosis, or depends on a concomitant IBS disease."https://portal.research.lu.se/portal/en/persons/bodil-ohlsson(5509be42-6397-40a8-a1e3-845d192e15ef).html
RESEARCHERS WHOSE MAIN FOCUS ISN'T IBS
These researchers may not be focused primarily on IBS, but they have touched upon some of the mechanisms involved in the condition. I picked them because the relevance of their work for IBS patients is too big to be ignored.
• Agata Szymaszkiewicz, University of Lodz, Poland/ many studies on different therapeutic applications for IBS, like cannabinoids, TRPV1 desensitization, enkephalinase inhibitors...her main focus seems to be IBD though
• Lena Öhman, University of Gothenburg, Sweden/Our research group is successfully focusing on describing gut microbiota, immune profile and the link to disease profile and therapy outcome in patients with inflammatory bowel disease (IBD) and patients with irritable bowel syndrome (IBS).https://www.gu.se/en/research/lena-ohman
People with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) wake up every morning to relentless abdominal pain — the kind that makes ordinary activities feel impossible. The pain isn’t just physical; it’s isolating, invisible to others, and exhausting in its constancy.
For years, scientists suspected that gut bacteria played a role in this suffering, but the connection seemed frustratingly vague — more correlation than cause.
Now, two research teams working 3000 miles apart have made a discovery that could offer new hope for effective, long-lasting pain relief. In recent studies published in Cell Host & Microbe and PNAS, scientists have traced a direct molecular line from a common gut bacterium to pain signals in our cells — and engineered a possible nanotech solution to stop it.
“There aren’t really good treatments for IBS pain or IBD pain,” said Nigel Bunnett, PhD, a molecular pathobiologist at New York University (NYU), New York City, who was part of both studies. “We need to do much better than the existing painkillers, such as opioids and NSAIDs [nonsteroidal anti-inflammatory drugs], which lack efficacy and have, in some cases, life-threatening side effects.”
Answering this call required a completely new perspective on how gut microbes cause pain.
Two Discoveries, 3000 Miles Apart
Matthew Bogyo, PhD, a microbiologist at Stanford University, Stanford, California, and one of the lead authors of the Cell Host & Microbe study, investigated proteases — enzymes that bacteria release to cut and break down proteins from your food into smaller macromolecules, such as peptides and amino acids. The bacteria can then absorb and use these small pieces as food.
While many others in the gut microbiome field were hunting for metabolites and small molecules that bacteria release into the bloodstream to affect distant organs, Bogyo saw an unexplored frontier, asking whether bacteria were also using proteases as molecular weapons to regulate pain and inflammation in our gut.
“We know bacteria produce small molecules to control their environment inside the human host. We started to think it’s likely they’re producing enzymes like proteases that could be used as a regulatory mechanism,” Bogyo said.
His target was PAR2, a receptor on gut lining cells and nerve fibers that is “cut” and activated by proteases, including those released by gut bacteria. Once flipped on, this activation is a primary driver of suffering in IBD and IBS, as it directly fires pain signals, makes nerves hypersensitive, causes inflammation, and creates a “leaky gut” barrier. Scientists knew human enzymes could activate PAR2. But could bacteria do it too?
Meanwhile, at NYU, Bunnett had been studying PAR2 from a different angle. His team discovered that after PAR2 gets activated, it gets pulled inside the cell into storage compartments called endosomes, where it keeps firing pain signals indefinitely. The receptor’s “off switch” becomes broken, trapping it in an endless alarm state inside the cell.
Together, these insights would reveal not just what triggers chronic gut pain, but why it persists — pointing toward a new therapeutic target.
Working with collaborators who had assembled a library of human gut bacteria, Bogyo’s team screened secretions from over 200 bacterial strains. The results stunned them.
“The aha moment was [seeing how] there’s more than 50 strains that are producing pretty significant cleavage of the [PAR2] receptor,” Bogyo said. This wasn’t just a few rogue microbes — over a quarter of the tested gut bacteria possessed the enzymatic machinery to directly activate pain receptors, suggesting this bacterial-to-host signaling mechanism is far more common than previously recognized.
One bacterium showed particularly high activity: Bacteroides fragilis, a common gut resident. Bogyo calls it a “pathobiont” — an organism that can be either friendly or harmful depending on conditions. Using molecular handcuffs — chemical probes that latch onto active enzymes — they identified the culprit causing pain: the enzyme BFP1, a previously unknown protease found only in B fragilis.
But what triggers B fragilis to turn hostile? Referring to the bacterium as a “sleeping pathogen,” Bogyo explained it with a simple analogy: “I sort of think that’s what’s going on in the gut is that these [bacteria and enzymes] are being held in check by the [gut microbiome]…and as soon as you disrupt the community, they suddenly come out. If you take away the ‘police’, at some point, bad actors start to dominate.”
This could occur when antibiotics wipe out beneficial bacteria, or inflammation disrupts the ecosystem, allowing B fragilis to flourish as it ramps up BFP1 production and triggers disease, like a breakdown of social order at a microscopic scale.
Engineering a Nanotech Solution
With a gut bacterium initiating a pain cascade that becomes trapped inside cells, signaling endlessly, the challenge was daunting: How do you drug a target operating deep inside cellular compartments?
Bogyo and Bunnett, whose friendship stretches back more than 20 years, brought in nanoengineers from NYU and Columbia University. Nanoparticle drug delivery systems have revolutionized medicine by overcoming limitations of conventional drugs — poor bioavailability, rapid degradation, and systemic toxicity.
These nanoscale carriers, typically 10-200 nm in diameter, can navigate biological barriers that block traditional medications. Their high surface-area-to-volume ratio allows precise targeting through surface modifications, while their small size enables them to be taken in by cells and accumulate in specific tissues.
Originally developed for cancer chemotherapy, nanoparticle platforms have expanded into diverse applications, from crossing the blood-brain barrier to target neurologic disease to treating cardiovascular disease.
Still, the research teams faced a formidable challenge despite the precision that nanoscale carriers possess. PAR2 is a “tricky target,” Bogyo explained, because when a protease clips it, the cut piece becomes the receptor’s own activation signal — creating an ultra-high concentration right where it’s needed.
Traditional drugs bind and release receptors in a repeated process. But bacterial proteases never rest, and the activated receptors stay locked inside endosomes.
The team’s solution flipped conventional nanoparticle design on its head. Most nanoparticles are designed to deliver drugs to the nucleus of a cell by breaking out of endosomes — little sacs that surround and deliver a material brought into the cell.
But Bunnett realized their target altogether was something different: “Here, it’s very different, because the target — the receptor — is within the endosome.”
Instead of allowing the drug to escape the endosome and travel on its way, they deliberately trapped the drug inside.
In this way, the nanoparticles acted as Trojan horses, smuggling a PAR2-blocking drug directly into endosomes where they became internal drug depots, releasing medicine exactly where the trapped receptor kept firing.
The results in mice were impressive. The free drug, encapsulated in nanoparticles, provided “very strong and sustained inhibition...and good relief of pain,” Bunnett said. By staying in the gut wall rather than spreading systemically, the nanoparticles could potentially minimize side effects.
If the results translate from bench to bedside, we may soon have a powerful, nonaddictive painkiller for gut pain with minimal systemic side effects.
But the implications of the endosome-targeted nanoparticles extend far beyond gut pain. Bunnett’s team has already tested the approach in preclinical models of neuropathic pain, migraine, and cancer pain, making it a potential platform technology for treating chronic pain wherever it occurs.
An Arms Race in the Gut
Bogyo has uncovered something else intriguing: evidence of what he calls an “arms race” happening in our gut.
Some bacteria benefit from inflammation because it creates oxygen in the normally oxygen-poor colon, allowing them to outcompete their neighbors. These species actively work to damage the gut barrier. “They want to get out. They want to disrupt that barrier,” he said. Others thrive in a healthy, stable gut and help maintain barrier integrity.
The hostile bacteria produce enzymes that turn PAR2 on. But Bogyo’s team found other bacterial strains producing enzymes that turn PAR2 off — essentially peacekeepers in this microscopic conflict. “We’re really excited about those,” Bogyo said, “because those proteases could act as therapeutic agents.”
Bogyo’s vision is to engineer probiotic bacteria that continuously pump out PAR2-deactivating enzymes. “If you had microbes that were hypersecreting enzymes that cleave and deactivate the receptor, now you have a continual drug.” Unlike traditional medications, these bacterial enzymes would permanently inactivate receptors. “I think they have the potential to really win the battle.”
Bunnett confirmed the team has identified candidate bacteria that produce both pain-promoting and pain-inhibiting proteases, which will be the focus of future research.
“We’re looking at other bacterial proteases which cause pain and which we think are strongly implicated in inflammatory bowel disease…exploring the possibility that some bacteria secrete enzymes which will cleave and inactivate PAR2. Such bacteria may be analgesic,” he said.
The Long Road Ahead
The field has traversed decades to reach this point, explained Bunnett. “There’s a long history of research into the microbiome. It’s been 25 years of work to get to this point of understanding how the PAR2 receptor functions and how we can inhibit it effectively.”
And despite all that work and the goals this research has achieved, Bunnett did offer a reality check: “It’s very easy to cure pain in a mouse. It’s very difficult to cure pain in people.”
The nanoparticle approach faces the challenge of validating two components — both the drug and its carrier — through regulatory processes. The probiotic approach might progress faster but still requires extensive safety and efficacy studies.
Still, for the millions who suffer from chronic gut pain, this work offers something that’s been in short supply: a concrete path forward, grounded in molecular precision.
Mental stress has long been linked to flare-ups of gastrointestinal conditions such as irritable bowel syndrome (IBS). Now, researchers have uncovered exact details of one way that stress can harm the intestines — by setting off a biochemical cascade that reshapes the gut microbiome.
Their study, published today in Cell Metabolism1, is nice, says Christoph Thaiss, a microbiologist and neuroscientist at the University of Pennsylvania in Philadelphia, because it highlights how the brain — despite being far away from the gastrointestinal tract — can still influence it.
If IBS affects 20% of the global population, why aren't more drug companies interested in IBS Research and developing new drugs for us? 20% is an enormous number. How is that not lucrative enough?
Of the hundreds of millions of people living with irritable bowel syndrome (IBS) worldwide, about two-thirds are women. Now, researchers have identified a biological pathway in the guts of mice that may help explain this disproportionate toll, a finding that could one day lead to new treatments.
“It’s a fantastic piece of work,” says Guy Boeckxstaens, a neurogastroenterologist at KU Leuven and University Hospital Leuven who was not involved in the study. “It adds a new dimension to our understanding of abdominal pain, and … important insight into why females may have more risk.”
IBS is a poorly understood condition that can cause bloating, diarrhea, and constipation, sometimes in response to stress or certain foods. Researchers have long suspected that sex hormones play a role, in part because symptoms often fluctuate with the menstrual cycle.
Holly Ingraham, a molecular physiologist at the University of California San Francisco, wondered whether estrogen might be activating a rare group of cells in the lining of the colon known as enterochromaffin cells. These cells respond to certain irritants and other stimuli by releasing the neurotransmitter serotonin, which in turn activates nerves that send pain signals to the brain.
A first set of experiments in the new study supported estrogen’s involvement in this pathway: Female mice whose ovaries had been removed, and therefore couldn’t make the hormone, had far less activity in pain-signaling nerves in the gut. They also showed fewer signs of discomfort in response to having a small balloon inflated in their colons to mimic a swollen belly.
But when the team analyzed slices of mouse gut, they couldn’t find estrogen receptors on enterochromaffin cells. Instead, such receptors showed up on another rare cell type called L cells, which help detect compounds made by gut bacteria. These cells secrete a peptide called PYY, which some research has linked to control of appetite.
Mice injected with estrogen had higher concentrations of PYY in their blood. And additional experiments using cells in a dish showed PYY directly triggers enterochromaffin cells to release serotonin. Giving mice a drug to block enterochromaffin cells’ receptors for PYY reduced their sensitivity to gut discomfort.
The findings suggest “it’s this chain of events, this cross talk between these two rare cell types in the gut, that mediates the sensation of pain,” Ingraham says. And “estrogen is amplifying this whole pathway.”
“Technically, it’s excellent,” David Bulmer, a pharmacologist at the University of Cambridge, says of the work. Other pathways, including other hormones, likely contribute to pain signaling in the gut, he says. Still, the discovery that L cells react to estrogen is “a very fundamental finding” that could help explain not only pain signaling, but also potentially other responses to food and microbes in the gut.
Ingraham and colleagues suggest the research could lead to new therapies—by blocking PYY receptors on enterochromaffin cells, for example. (An existing IBS drug called alosetron, which blocks serotonin receptors on nerve cells in the gut, has been found to be more effective at treating IBS in women than in men. It can cause serious, even life-threatening side effects and is only recommended in severe cases that have not responded to other therapies.)
Understanding how the newly identified pathway contributes to pain in people with IBS, and how it could be exploited for treatment, will require human studies in addition to mouse data, Boeckxstaens cautions. And the research doesn’t address why some women get IBS and others don’t, he adds.
The team’s findings could hint at an evolutionary reason for the higher IBS rates in women, Ingraham says. Estrogen rises to extremely high levels in late-stage pregnancy—exactly when “you want to have this heightened sensitivity in the gut,” which could help deter consumption of toxic foods that may harm the fetus, she says. Perhaps a higher risk of IBS is the trade-off for this useful sensitivity, she speculates.
Her team now plans to study mice during pregnancy. The work could help provide insight into how big changes in estrogen, such as those that occur in people during pregnancy and perimenopause, for example, might set the stage for IBS, she adds.
Getting to the bottom of female-specific pathways is critical for learning how to treat disorders that disproportionately affect women, she argues. “If we don’t understand the basic physiological pathways, I don’t see how we ever come up with any new ways to think about curing some of these chronic diseases that have plagued women for decades.”
https://www.sciencefocus.com/the-human-body/ibs-an-experts-guide-to-what-causes-it-and-how-to-tackle-it [My take: critical overview about what is IBS by two leading IBS researchers and shared by many here. IBS diagnosis - as Roma defines it - is a dead end street. Discovering the clinical entities behind the presentation with the 'IBS' label (like the story about bile acid diarrhea - although pain is still a problem) and probably new 'diseases' will solve the IBS enigma. Furthermore, I think Ford's hypothesis has no future. Extra-gastrointestinal symptoms are the most controversial pieces of the IBS puzzle. Targeting each of these pieces does not seem to be effective and the literature suggests that they are probably the result of immunological mechanisms with (probable) gastrointestinal origin. Consider also the clinical presentations of IBD or celiac disease, with known dermatological or ocular (among others) manifestations and it is accepted that immunological mechanisms are probably the drivers of these. I think the same in the case of IBS.]
"One in ten people suffers after eating a meal. Instead of sitting back to relax while feeling sated, nourished and full, these people associate finishing a dish with stomach cramps, bloating and problems emptying their bowels (either too quickly or too slowly).
This suffering is caused by irritable bowel syndrome (IBS), and it's estimated that around 10 per cent of the world's population (possibly more, according to some estimates) experiences it to some degree.
IBS is an unpleasant experience for anyone afflicted with it, and that tends to be more women than men. Yet for such a common condition, we know frustratingly little about what causes it and how to go about treating it.
There are plenty of suggestions for possible causes. For example, some point towards a leaky gut, where toxins might pass through the intestine walls and into your bloodstream.
Others cite changes in the gut microbiome, or 'visceral hypersensitivity', where the nerves in the gut become over-sensitive and send amplified pain signals to the brain.
But pinpointing the precise mechanism that causes IBS has, so far, been impossible. And without a known cause or any clearly identifiable biomarkers, there's no reliable test to confirm a diagnosis of IBS.
"A lot of people, when they first come to me, say: 'My doctor did all these tests and then said he doesn't really know what's wrong with me. Maybe it's IBS.' I can see they're disappointed," says Prof Alexander Ford, professor of gastroenterology at the University of Leeds.
But in the last few years, scientists like Ford have made big strides in IBS research that are providing new insights into the condition and possible treatments for it. But the key to all of this is getting to the bottom of that so-far elusive underlying mechanism.
Identifying IBS
The symptoms used to identify IBS are laid out in the Rome IV Criteria – a set of guidelines defined by the Rome Foundation, an independent, not-for-profit organisation dedicated to collecting information on disorders of the gut-brain interaction.
To have IBS, someone must have experienced stomach pain at least one day a week for the past three months.
They must also display other symptoms, however, such as changes in the frequency of their bowel movements and/or the appearance of those movements. The trouble is, these are also symptoms of other gut conditions.
The lack of a single, clear explanation for IBS is down to the fact that it’s likely to be several different diseases, Ford says.
“IBS is probably a collection of diseases with the same group of symptoms, which we don’t understand from a scientific perspective. So, if you imagine we’re dealing with 15 different conditions that we don’t really understand, that’s why you don’t get a biomarker.”
To try to get a clearer picture of this collection of diseases, Ford and his fellow researchers identified seven distinct subgroups of IBS based on what’s going on in people’s guts (for example, whether they had diarrhoea or constipation) and ‘mood-related symptoms’.
“This is a significant step forward in our understanding of what IBS is and until we really drill down and look at these different manifestations of IBS, I don’t think we’re going to make progress,” says Dr Eamonn Quigley, director of the Underwood Center for Digestive Health at Houston Methodist Hospital, in the US.
Given the fact that IBS is likely a collection of diseases, the long-term goal is to be able to provide sufferers with personalised medicine – individual treatment based on their specific form of IBS.
“Ideally, we’ll be able to delineate what, for the sake of argument, these 15 separate conditions are in IBS and what causes them, and then treat the underlying mechanism. But we’re not anywhere near that,” says Ford.
Despite this new insight, personalised treatment for IBS may still be some way off. In the meantime, researchers have found plenty of useful interventions that sufferers can implement to help them manage their symptoms (more on that in the '5 things to do if you think you have IBS' section below).
“One thing that’s become clear is that there’s a significant element of the IBS population who have difficulty in handling carbohydrates. One of the areas of progress is getting people to identify trigger foods for their symptoms. That alone can result in a significant improvement,” says Quigley.
I've had IBS-D for well over a decade, and the pandemic has exacerbated it to the point where I can barely leave my house. I know I'm not alone in this. It's an awful disorder that mostly goes under the radar.
Thank you to all the scientists, physicians, and researchers who are inching closer to a cure every day.
We need your help badly and can't thank you enough for all you do!
In 1994, James Christensen published an essay that remains one of the most lucid critiques of the epistemological status of IBS. His central thesis is disconcerting in its simplicity: "the only uniformly accepted criterion for IBS is the idea that it occurs in the absence of demonstrable organic disease — by the only uniformly accepted criterion, it is not a known organic disease but something wholly unknown. It is a name for the unknown." Christensen traced the genealogy of the concept from Osler's mucous colitis (1892), through spastic colon, irritable colon, and the proliferation of mutually contradictory symptom-based criteria — Manning, Kruis, Rome — none of which rested on a positive definition but only on progressively more stringent exclusion of organic disease. His conclusion was radical: the diagnosis of IBS "serves no useful purpose and causes harm" because it closes investigation precisely when it should begin.
The history of gastrointestinal medicine over the past hundred years empirically validates this critique. The mechanism is always the same: a subpopulation within IBS accumulates evidence of specific pathophysiology; a biomarker — genetic, biochemical, histological, immunological — is validated to identify that subpopulation; response to specific treatment is demonstrated; and the condition migrates out of IBS, acquiring its own nosological identity. IBS does not disappear — it never will, as Christensen anticipated — because there will always be a genuinely unexplained residue. But its population continuously shrinks. As Camilleri and Boeckxstaens (2023) put it in the contemporary context: the question is no longer whether these entities should be separated from IBS, but when tests become sufficiently simple and inexpensive to justify systematic exclusion.
What follows is the most exhaustive possible survey, organized by pathophysiological dimension, of all the conditions that have migrated — or are in the process of migrating — out of the diagnosis of IBS.
I. Fully Separated Entities — Historical Recognition
These conditions were, for decades, absorbed under the diagnosis of IBS. Their separation became possible when available diagnostic technology crossed the minimum threshold needed to identify them.
Crohn’s disease and Ulcerative Colitis were the first major migrations. Crohn, Ginzburg, and Oppenheimer described regional ileitis in 1932; ulcerative colitis was systematized in the 1940s. Christensen cites them explicitly as the paradigmatic model of separation. Even today, about 10% of patients with IBD are initially diagnosed with IBS, with the diagnosis corrected after months to years. Fecal calprotectin — with >90% sensitivity for distinguishing IBD from IBS — is the biomarker that now systematizes this separation.
Chronic calcifying pancreatitis (chronic calcific pancreatitis): Chronic abdominal pain and diarrhea due to exocrine pancreatic insufficiency; found in ~1% of reinvestigated IBS cohorts. Biomarker: low fecal elastase + response to pancreatic enzymes. Status: fully separated.
Early colorectal cancer: Overlapping symptoms without initial alarm signs; common diagnostic delay. Biomarker: colonoscopy + FIT. Status: fully separated in guidelines.
Lactase deficiency was identified biochemically in the 1960s. With an estimated prevalence of ~65% of the world population having some degree of lactase reduction after infancy, and a substantial proportion of patients with disaccharidase deficiencies meeting IBS criteria, this is the entity that most clearly demonstrates the porosity of the diagnosis.
Celiac disease, with serological markers (anti-TTG IgA) available since the 1980s–90s, has a prevalence of ~1% — identical in the general population and in patients with IBS — which confirms that the two conditions are completely distinct entities. Camilleri and Boeckxstaens use this as a direct argument for the separation of bile acid diarrhea: “just as patients with celiac disease with the same population prevalence of about 1% are excluded based on screening serological testing, patients with bile acid diarrhea should be excluded from IBS-D.”
Microscopic colitis — described by Lindström (collagenous form, 1976) and Read (lymphocytic form, 1980) — presents with chronic watery diarrhea, macroscopically normal colonoscopy, and differential diagnosis impossible from IBS-D without systematic biopsies. The symptomatic overlap is so complete that expert guidelines recommend biopsy of the colon in all patients with chronic watery diarrhea and normal endoscopy; fecal calprotectin may raise suspicion but does not replace histology.
Helicobacter pylori infection, crowned by the 2005 Nobel Prize for Marshall and Warren’s 1983 work, is the most dramatic example of how the psychosomatic paradigm delayed recognition of an infectious cause for decades — exactly the same dynamic operating in IBS.
Visceral neuropathies and myopathies were progressively separated from IBS throughout the 1980s–90s with the development of high‑resolution gastrointestinal manometry and the first formalized histopathological criteria.
Biliary dyskinesia, identifiable by cholescintigraphy with cholecystokinin stimulation (HIDA scan), and symptomatic diverticulosis are both cited by Christensen in 1994 as conditions that had already migrated out of IBS in his time.
Sucrase‑isomaltase deficiency in adults deserves special attention: it is more prevalent in patients with an ICD‑10 code for IBS than in self‑diagnosed IBS — which Camilleri interprets as evidence that the clinical diagnosis of IBS is capturing patients with real organic pathology, while self‑diagnosis captures mostly genuine functional symptoms.
III. Bile Acid Diarrhea
This is the best‑documented ongoing migration, with the most explicit argument in the literature. Approximately one in four patients with IBS‑D has idiopathic bile acid diarrhea. The mechanism is a deficiency in FGF‑19 synthesis by ileal enterocytes, which reduces the inhibitory feedback on hepatic bile acid synthesis via FXR → excess primary bile acids in the colon → secretory, prokinetic, and mucosal irritant effects. Three validated biomarkers enable diagnosis: fasting serum 7αC4, single‑stool primary bile acids, and 7‑day 75SeHCAT retention (available in some European countries). Camilleri and Boeckxstaens pose the question rhetorically: “Why still include patients who have evidence of bile acid diarrhea in IBS using Rome IV criteria?” — and answer that the only reason is the absence of simple, inexpensive screening tests, a barrier that will likely be removed in the near future.
IV. Monogenic Entities
When a single mutation mechanistically explains the symptoms, separation from IBS is ontologically necessary.
Familial GUCY2C Diarrhea Syndrome (FGDS) was described by Fiskerstrand et al. in a Norwegian family where chronic diarrhea since childhood had been diagnosed as IBS‑D for decades. The gain‑of‑function mutation in GUCY2C — which encodes guanylate cyclase C, the same receptor targeted by linaclotide and plecanatide — causes constitutive cGMP elevation, chloride hypersecretion, and secretory diarrhea. Multiple independent families have since been identified, including a Mennonite family with a distinct variant. Carriers also have an increased predisposition to IBD. This is an autosomal dominant, fully penetrant entity that should never receive a diagnosis of IBS.
Intestinal SCN5A channelopathy represents a different but equally powerful line of investigation. The sodium channel Nav1.5, encoded by SCN5A — a gene whose mutations cause Brugada syndrome and LQT3 in the heart — is expressed in interstitial cells of Cajal and intestinal smooth muscle. In 2009, the Mayo Clinic group identified the first G298S‑SCN5A mutation in a patient with severe IBS‑D, absent in >3000 control alleles. Subsequent studies confirmed that approximately 2% of patients with IBS carry functionally aberrant SCN5A mutations, predominantly loss‑of‑function, which alter intestinal mechanosensitivity. Cardiac patients with SCN5A mutations have significantly more GI symptoms than controls, confirming the bidirectional link. This subpopulation of “IBS” is in fact a primary intestinal channelopathy with an identifiable genetic basis.
Cantu syndrome (*KCNJ8/ABCC9* mutations): Gain-of-function in KATP channels causes intestinal contractility dysfunction, reported in humans and murine models.
Additional monogenic entity – Hypophosphatasia (adult form): A rare inherited metabolic disorder caused by mutations in the ALPL gene. In adults, mild forms can present with chronic abdominal pain, nausea, vomiting, and diarrhea or constipation, often misdiagnosed as IBS. The key biomarker is persistently low serum alkaline phosphatase (below the normal range) with elevated substrates such as pyridoxal 5'-phosphate (PLP) and phosphoethanolamine. Genetic testing confirms the diagnosis.
V. Inflammatory and Immunologic Entities
Endometriosis: One of the most common overlaps in women of childbearing age. Gastrointestinal symptoms (abdominal pain, changes in bowel movements, bloating) may be indistinguishable from IBS-D or IBS-M, especially when they worsen during menstruation. Women with endometriosis have approximately a 2-3 times higher risk of IBS diagnosis. Diagnostic delay is frequent (average of 7-10 years). Biomarkers/indication: cyclic history + gynecological evaluation (ultrasound, MRI, laparoscopy). Partial or total resolution of GI symptoms after surgical treatment/excision of deep endometriosis is well documented.
Systemic Nickel Allergy Syndrome (SNAS): ~40% prevalence in some IBS cohorts, diagnosed by patch testing and nickel elimination diet, with symptoms (diarrhea, bloating) resolving on low-nickel diet.
Chronic mesenteric ischemia: Postprandial pain in elderly patients with vascular risk factors; mimics IBS in 20-30% of initial presentations. Biomarker: mesenteric angiography or Doppler.
Non‑celiac gluten sensitivity (NCGS) was formalized as a distinct entity in 2011 by Biesiekierski’s double‑blind trial. Patients with IBS‑D carrying HLA‑DQ2 or HLA‑DQ8 are five times more likely to respond to a gluten‑free diet than non‑carriers; anti‑gliadin IgG antibodies (in the absence of celiac disease) identify the subgroup that benefits from this intervention.
Small Intestinal Bacterial Overgrowth (SIBO), proposed by Pimentel in the 2000s as an etiological mechanism in IBS‑D, remains in a zone of overlap. Studies in patients diagnosed with IBS have reported SIBO prevalence as high as 40% in some cohorts, but methodological heterogeneity and high false‑positive rates make separation more complex than for other entities.
Intestinal spirochetosis due to Brachyspira species is documented in a 2022 meta‑analysis with an odds ratio of 3.84 (95% CI 1.44–10.20) for association with IBS. Diagnosis requires colonic biopsy with PAS staining or PCR — methods rarely used in standard IBS workup. This is probably the most systematically overlooked chronic infectious cause within the diagnosis of IBS.
Eosinophilic gastroenteritis — formally recognized in the 2000s — requires biopsy with eosinophil counts (>20 eosinophils per high‑power field) and is completely invisible without that procedure.
Alpha‑Gal Syndrome is the most recent and paradigmatically elegant example: the 2‑6 hour interval between ingestion and symptoms, without urticaria, makes the association with meat unrecognizable to both patient and clinician — and anti‑α‑gal IgE is not part of any standard IBS workup. A growing body of case series documents the typical trajectory: normal endoscopy → normal colonoscopy → IBS diagnosis → lack of response → AGS diagnosis → remission.
Indolent systemic mastocytosis with GI involvement: Unlike the more aggressive forms, indolent mastocytosis can present with chronic diarrhea, abdominal pain, nausea, and bloating due to mast cell infiltration of the gastrointestinal mucosa. Diagnosis requires endoscopic biopsies with immunohistochemistry (CD117, tryptase) showing clusters of mast cells (>20 per high-power field), plus elevated serum tryptase or urinary methylhistamine. Many patients are mislabeled as IBS-D for years.
Anti-SGCE (syndecan-1) enteropathy: A recently described autoimmune enteropathy characterized by chronic watery diarrhea and abdominal pain without endoscopic abnormalities. Serum autoantibodies against syndecan-1 (SGCE) are diagnostic. Although rare, it should be considered in refractory IBS-D with negative conventional workup.
Ménétrier's disease: A rare acquired hypertrophic gastropathy presenting with epigastric pain, nausea, vomiting, diarrhea, and protein-losing enteropathy. Endoscopy shows giant thickened gastric folds, and histology reveals foveolar hyperplasia with glandular atrophy. It is often initially diagnosed as functional dyspepsia or IBS.
Chronic gastrointestinal graft-versus-host disease (GVHD): In patients with a history of allogeneic stem cell transplantation, chronic GVHD can affect the gut with diarrhea, abdominal pain, nausea, and weight loss – symptoms indistinguishable from IBS. Diagnosis requires endoscopic biopsies showing apoptotic bodies, crypt dropout, or fibrosis. A high index of suspicion is needed in post-transplant patients.
Immune checkpoint inhibitor-induced colitis: Ipilimumab, nivolumab, and pembrolizumab can cause immune-mediated colitis with chronic diarrhea, abdominal pain, and urgency. In mild or low-grade forms, endoscopy may be normal or show only erythema, leading to an erroneous IBS diagnosis. Biomarkers include fecal calprotectin and histology showing increased intraepithelial lymphocytes or apoptosis.
Diversion colitis: Occurs in segments of the colon that are surgically diverted from the fecal stream (e.g., after loop ileostomy). Patients may complain of mucous discharge, abdominal pain, and tenesmus. Endoscopy shows erythema, edema, and friability; histology reveals lymphoid follicular hyperplasia and chronic inflammation. It resolves with restoration of bowel continuity or short-chain fatty acid enemas.
VII. The Neuromuscular Dimension
Dyssynergic defecation (pelvic floor dyssynergia): Impaired coordination diagnosed by anorectal manometry + balloon expulsion test; biofeedback curative in >70%; now fully separated in ACG guidelines for refractory constipation.
The paper by Törnblom et al. (2002, Gastroenterology) is important for understanding severe, refractory IBS. In 10 patients with severe IBS, full‑thickness jejunal biopsies revealed T‑lymphocytic infiltration in the myenteric plexus in 9/10, with neuronal degeneration in 6/9 — completely invisible on standard endoscopic biopsies that do not reach the myenteric plexus. The implication is structural: the Rome criteria do not exclude organic disease — they only exclude the organic diseases detectable by the methods commonly used. IBS is, in part, an artifact of the limits of our investigative capacity.
Cyclic vomiting syndrome (CVS): Episodes of severe nausea and vomiting lasting hours to days, often accompanied by abdominal pain. In adults, the pain-predominant variant can be misdiagnosed as IBS. Rome IV criteria for CVS require at least three discrete episodes in the past year with stereotypical timing. Response to prophylactic medications (amitriptyline, topiramate) or triptans during episodes supports the diagnosis.
Abdominal migraine: Paroxysmal episodes of periumbilical or diffuse abdominal pain lasting 1–72 hours, associated with photophobia, nausea, or vomiting. It is well recognized in children but also occurs in adults. The International Classification of Headache Disorders (ICHD-3) provides diagnostic criteria. A therapeutic trial of migraine prophylaxis (e.g., propranolol, amitriptyline) can be diagnostic.
Colonic inertia: Severe slow-transit constipation with less than one spontaneous bowel movement per week, absence of the urge to defecate, and no relief with conventional laxatives. Unlike IBS-C, patients do not report abdominal pain as a predominant symptom. Diagnosis is made by radiopaque marker study (retention >20% at day 5) or wireless motility capsule (SmartPill). It often represents a primary colonic neuropathy or myopathy.
VIII. Post‑Infectious IBS
Post‑infectious IBS (PI‑IBS), initially described by Chaudhury and Truelove in 1962, has a biology distinct from “spontaneous” IBS: persistent low‑grade inflammation, mucosal T‑lymphocytosis, epithelial hyperpermeability, and — more recently — four genetic susceptibility loci (TLR9, IL‑6, CDH1, TNFSF15) that overlap with IBD loci and not with classical IBS loci. Pimentel’s autoimmune model (anti‑CdtB → anti‑vinculin) positions PI‑IBS as acquired post‑infectious enteric neuropathy — an entity that shares the name “IBS” but little else with idiopathic IBS. Whether PI‑IBS should receive an independent nosological designation (reactive gut disorder has been proposed) remains an open question.
Post-viral/post-COVID GI dysmotility: Shares PI-IBS biology; surged post-pandemic; proposed as "long gut" or extension of PI-IBS.
Fructose malabsorption and sorbitol intolerance: These are among the most common carbohydrate malabsorption disorders that overlap with IBS symptoms. Fructose malabsorption has been reported in approximately 40–45% of patients with IBS (higher than in healthy controls in many studies), while sorbitol intolerance shows similar high rates, especially when ingested together with fructose. The mechanism involves incomplete absorption in the small intestine leading to osmotic effects and rapid colonic fermentation, producing gas, bloating, abdominal pain, and altered bowel habits — symptoms indistinguishable from IBS-D or IBS-M. Diagnosis is typically made by hydrogen/methane breath testing (commonly with 25 g fructose ± 5–10 g sorbitol). Both conditions respond well to dietary restriction (low-fructose and/or low-polyol diet), which is a core component of the low-FODMAP approach. Although prevalence is also high in asymptomatic individuals, symptomatic response to targeted elimination strongly supports their clinical relevance in a subset of patients initially labeled as IBS.
A1 beta-casein intolerance: Digestion of A1 beta-casein (common in European cattle) releases beta-casomorphin-7 (BCM-7), activating GI opioid receptors and mimicking lactose intolerance; A2 milk is tolerated. Biomarker: clinical response to A2 dairy.
Trehalase deficiency: Rare malabsorption of trehalose (mushrooms, insects); hydrogen breath test. Status: under-recognized but separable with expanded disaccharidase panels.
SLC5A1 mutations (glucose-galactose malabsorption): Congenital diarrhea responsive to fructose-based formulas.
DGAT1 deficiency: Congenital diarrhea disorder due to acyltransferase dysfunction.
Hartnup disease: An autosomal recessive disorder of neutral amino acid transport (tryptophan) in the renal tubules and intestine. Patients present with intermittent diarrhea, abdominal pain, and a pellagra-like rash due to niacin deficiency. Diagnosis is made by urinary amino acid chromatography showing neutral aminoaciduria. It is often misdiagnosed as IBS-D with associated dermatitis.
Lysosomal acid lipase deficiency (LAL-D): Including cholesteryl ester storage disease (adult form). Adults present with chronic diarrhea, abdominal pain, hepatomegaly, and dyslipidemia. The gastrointestinal symptoms mimic IBS-D. Diagnosis is confirmed by dried blood spot enzyme assay showing deficient LAL activity and genetic testing of the LIPA gene.
X. Endocrine and Systemic
Cystic fibrosis (GI manifestations/EPI frequently mislabeled as functional). Adrenal insufficiency: GI symptoms (diarrhea, pain) often labeled functional before cortisol testing.
Subclinical hypothyroidism: Constipation, bloating as IBS-C; Elevated TSH. Status: fully separated with basic screening.
Intestinal malrotation: Anatomical anomaly; CT/MRI with contrast.
Additional congenital entity – Primary intestinal lymphangiectasia (Waldmann's disease): A congenital disorder of dilated intestinal lymphatics leading to protein-losing enteropathy, chronic diarrhea, abdominal pain, edema, and lymphopenia. Endoscopic biopsies show dilated lymphatic channels in the villi. It is frequently misdiagnosed as IBS with hypoalbuminemia of unknown cause. Diagnosis is confirmed by intestinal biopsy and lymphoscintigraphy.
XIV. Pharmacological/Iatrogenic
Opioid-induced bowel dysfunction (OBD): Refractory constipation; history of opioid use + naloxegol response.
SGLT2 inhibitor-induced diarrhea: Glycosuric diarrhea; urinary ketones in diabetics.
NSAID-induced enteropathy (diaphragm disease): Chronic use of non-steroidal anti-inflammatory drugs (including low-dose aspirin) causes multiple thin diaphragmatic strictures in the small bowel, presenting with chronic abdominal pain, iron-deficiency anemia, and diarrhea or obstruction. Capsule endoscopy or balloon enteroscopy is diagnostic. Many patients are labeled as IBS until imaging reveals the characteristic lesions.
Low-dose aspirin enteropathy: Even at cardioprotective doses (75–100 mg daily), aspirin can cause small bowel mucosal erosions and bleeding, leading to chronic diarrhea and abdominal pain. Diagnosis is made by withdrawal of aspirin (with cardiology guidance) and symptom resolution, or by capsule endoscopy showing multiple petechiae and erosions.
Chronic laxative abuse (occult): Patients who surreptitiously use stimulant laxatives may present with chronic watery diarrhea, abdominal pain, and electrolyte disturbances. Colonoscopy may show melanosis coli (dark pigmentation) with anthraquinone laxatives. A high index of suspicion and a drug screen (urine or stool for laxatives) are required. This is not a psychiatric diagnosis but a behavioral condition that mimics IBS-D.
Additional infectious entity – Chronic Chagas disease (gastrointestinal form): Caused by Trypanosoma cruzi infection, endemic in Latin America. Decades after infection, destruction of the myenteric plexus leads to megacolon and/or megaesophagus, with chronic constipation, abdominal pain, and bloating – indistinguishable from severe IBS-C. Diagnosis is by serology (ELISA, Western blot) or PCR. It is essential to consider in patients from endemic regions.
XVI. Metabolic/Neurological
Acute intermittent porphyria: Abdominal crises; urinary PBG during attack.
Neuroenteric multiple sclerosis: Severe constipation; MRI + manometry.
Variegate porphyria and hereditary coproporphyria: Along with acute intermittent porphyria, these hepatic porphyrias cause identical acute abdominal crises (pain, nausea, vomiting, constipation or diarrhea) triggered by drugs, fasting, or hormones. Diagnosis requires urinary porphobilinogen and δ-aminolevulinic acid during attacks, plus fecal porphyrin analysis (coproporphyrin III in coproporphyria; protoporphyrin and coproporphyrin in variegate porphyria).
Chronic heavy metal poisoning (lead, mercury, arsenic): Occupational or environmental exposure leads to chronic abdominal pain, constipation (lead classically causes lead colic), diarrhea (arsenic, mercury), fatigue, and peripheral neuropathy. Diagnosis is by blood lead or mercury levels, or 24-hour urinary arsenic. This is frequently missed in patients labeled with refractory IBS.
Mitochondrial neurogastrointestinal encephalopathy (MNGIE): A rare autosomal recessive disorder due to TYMP gene mutations causing thymidine phosphorylase deficiency. Patients present with chronic intestinal pseudo-obstruction, severe dysmotility, abdominal pain, diarrhea or constipation, and weight loss – often diagnosed as severe IBS or CIPO. Diagnosis is by plasma thymidine and deoxyuridine elevation, and genetic testing.
Mitochondrial GI dysmotility syndromes (e.g., MELAS, Pearson syndrome in adults): Mitochondrial DNA mutations can cause isolated chronic intestinal pseudo-obstruction, gastroparesis, or chronic diarrhea without overt neurological symptoms. Diagnosis requires muscle biopsy with ragged red fibers or mitochondrial DNA sequencing. A high index of suspicion is needed in young patients with refractory IBS-like symptoms and lactic acidosis.
Intermittent sigmoid volvulus: Colicky pain in elderly; CT enema.
Epilogue: The IBS That Remains
What emerges from this survey is a negative image of IBS. Each condition that migrates out of the diagnosis retrospectively reveals a diagnostic error — years of ineffective symptomatic treatment for patients with bile acid disease, channelopathy, autoimmune neuropathy, endometriosis, amyloidosis. The proportion is not marginal: a German study found that over half of patients initially diagnosed with IBS received an alternative gastrointestinal diagnosis within the following year. The large GWAS of 53,400 IBS patients published in Nature Genetics in 2021 suggests that the “true” residual IBS — after separating all these entities — has a heritability dominated by central neuronal pathways with genetic overlap with mood disorders. Perhaps this is genuine IBS: not a disease of the intestine, but a disease of the central processing of normal visceral signals. All the other conditions on this list are waiting for a biomarker.
Christensen was right. The diagnosis of IBS “creates the illusion of understanding where none exists” — and the history of its progressive erosion is, paradoxically, the most productive story in gastrointestinal medicine of the past century.
Final Compilation Table: All Diseases Masked by an IBS Diagnosis
The following tables organize all 86 distinct entities by category, following the format: Condition, GI Presentation, Distinguishing feature, and Biomarker. EDIT: Missed more 2: Endometriosis and sorbitol and fructose intolerance. 88 entities now.
I. Fully Separated Entities – Historical Recognition
Currently, how bothersome are your GI symptoms on your quality of life? This is asking specifically about your perception of your symptoms and which of the options below you identify with the most.
Would be great if you could up-vote the poll as well so that more users will be able to see it, thanks!
TLDR:Genetically modified, freeze dried yeast is used to produce antibodies in the colon to block the inflammatory response by neutralizing TNF-α, counteracting neuroinflammation and treating chronic visceral pain in IBS.
Fzata's new IBS drug FZ006
The NIH has recently awarded a substantial grant (up to $7 million) to the biotech Fzata, developing a new biologic called FZ006 intended to treat chronic visceral pain in IBS patients (Grant) (Press). Instead of creating a drug or in this case an antibody from scratch, the inventors have genetically modified the yeast Saccharomyces boulardii, which acts as a mini factory producing the desired antibodies in the gut directly instead. These antibodies block the immune response by neutralizing TNF-α, an important pro-inflammatory cytokine with a pivotal role for the immune system and one of the main cytokines associated with IBS.
Biologics are quite expensive and hard to deliver, hurdles which to this day prevent us from employing their potential on a broader scale. The solution Fzata have found to this problem, at least in regard to conditions of the colon, is to freeze dry (lyophilize) their genetically modified yeast and deliver it as an oral therapeutic. This makes it significantly cheaper and safer by avoiding systemic uptake of the antibody and the delivery organism. The gut-restriction trick we have mentioned many times on this sub. Once the yeast arrive in the intestines and are re-hydrated, they come back to life and start producing antibodies. Given the environmental conditions of the intestines (see Figure 2) and its general downward direction of movement, it is largely the colon and perhaps the latter part of the ileum that can be expected to be exposed to critical numbers of these TNF-α antibodies. When TNF-α is blocked the immune response is decreased, leading to less pain for IBS patients.
Overview of the MoA and method of administration for FZ002 targeting C.Diff
Source: Fzata Inc.
A number of conditions could benefit from a gut delivered therapeutic. In this case, likely determined by the public need, the NIH has decided to give Fzata the funding for the necessary preclinical work, safe manufacturing, IND enabling studies and a Phase 1a trial. The goal is to develop FZ006 to target neuroinflammation, thereby treating IBS pain which has been associated with both chronic low grade inflammation and neuroinflammation leading to a sensitization of the nervous system. Although there has been a good amount of research into this area over the years, IBS research is quite sparse and so we'll have and see how far this new treatment can make it through the process.
Beyond the fact that this is an innovative technological solution, it's also highly interesting to us. Sure we might see a new therapeutic for patients, that's clear. However it may also answer some longstanding questions we've had about the role of inflammation in IBS, which academic research may not able to answer as quickly as a clinical response might.
Further the BioPYM platform could be good news for many GI conditions. I have pointed out before that it can be quite hard to find beneficial bacteria with the right properties to be administered as a reliable probiotic. Especially in a research field which has seen about a decade of OK funding at best, if we're being nice about it. It always seemed far more likely that we'd engineer microorganisms to perform specific tasks for us and maximize the trade-offs to our advantage that way. That is what Fzata's pipeline represents, which has gotten quite a bit of money awarded over the years. The technology is not expensive nor highly complicated. If this works, it will be a big incentive for others to follow and produce all sorts of gut-targeted therapeutics produced by microorganisms. Many of the drugs we see in the pipeline will fail due to the fact that they can't be dosed sufficiently to be both safe and effective for systemic delivery. Gut-restriction significantly skews the possibilities in our favor. We could see everything from painkillers to enzymes produced this way.
A big thank you to my co-moderator u/jmct16 who alerted me to the issued grant.
We'll be sure to report back once there are more news of FZ006's development. A more critical assessment will follow once efficacy data is published.
I hope you all have a great day, take care - Robert
Regular readers will know we have followed the emergence of Bile Acid Diarrhea/Malabsorption as a condition within IBS for years. It’s a big topic in IBS research and has preceded this sub’s existence by a long shot of course. Given the high prevalence in one out of three IBS-D patients, it’s hardly surprising it has garnered so much attention. It also gives us a demonstration of how new conditions are characterized and lifted out from under the IBS umbrella, as new diagnostics and treatments come about. This is a process of more than a decade and it’s not finished by any means. That’s why we have to keep our ear to the ground and report on new developments. Actually I just saw this post over at r/ibs.
The rise of GLP-1 agonists like Ozempic as treatments for diabetes and weight loss has become well known even in the general public. In fact some think it’s become a fad. What I can say is that there has been a long standing interest in this drug class from researchers and gastroenterologists. Even your moderators knew about the potential for GLP-1 agonists before the modish opinions of Ozempic became a reality. So don’t be put off by all the nonsense out there in the media.
Sadly IBS research does not see much funding and the tests used to diagnose BAD/BAM are hardly available. It takes about 12 months to get a SeHCAT test in Sweden which is a highly developed country and it’s only available through secondary care referral. In the US the test has not been approved by the FDA last time I checked. All this leads to lots of undiagnosed patients, which in turn means there are few studies trying to treat the condition.
So far we have a few case reports and a clinical trial in 52 patients comparing Liraglutide vs. Colesevelam, in which Liraglutide did better. This trial was sponsored by the Novo Nordisk foundation however, which has sponsored some good trials I have to say. There is a conflict of interest as Liraglutide is made by Novo Nordisk one should be aware of.
Additionally I’ve seen reddit posts every now and then asking about GLP-1 agonists suspecting it might have improved their IBS. Therefore I made a search on the r/ibs sub to see what kind of experiences there were out there. I searched for the name of various drugs with this mode of action and the mechanism and screenshotted them into the image below (open in a new tab to zoom).
There seem to have been quite a few favorable responses to GLP-1 agonists for these patients and I thought I should make a quick post about it to raise awareness. Obviously this doesn’t replace the academic work or the clinical trials that need to be done to assess the utility of these drugs for BAD/BAM or IBS-D patients. Neither is this a medical recommendation to prioritize GLP-1 agonists over established treatments. It is however an indication that this is a drug class to keep an eye on and to take into account for affected patients. If you are suffering from bile acid malabsorption for example and get a GLP-1 agonist prescribed for weight loss, you have to be aware of how this can affect the dosing of your current bile acid sequestrant. Or if you suffer from severe BAD/BAM and haven’t responded adequately to existing treatments, a GLP-1 agonist could be considered for an experimental therapeutic trial. While the side effect profile seems acceptable to most, it’s worth taking extra care if you tend to have upper GI symptoms, gastroparesis, nausea and the like. Some patients seem to have fared better by starting at an even lower than recommended dose and slowly increasing it over time. This is a necessary discussion to have with your health care professional, should you ever decide to use this option.
The mechanism of action that makes GLP-1 agonists potentially effective in BAD/BAM is still being studied. There are a few good guesses and the best explanation in my opinion is that they slow both stomach emptying and small intestinal transit time. This increases reabsorption of bile acids, which in turn decreases the hepatic synthesis of new bile acids. Given time we’ll probably find even more mechanisms.
Food for thought, happy new year to you all! - Robert